New drug cocktail aims to control rare blood cancer without lifelong treatment
NCT ID NCT07231952
First seen Nov 17, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This phase 2 study is testing a time-limited combination of three drugs—pirtobrutinib, venetoclax, and rituximab—in 40 patients newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this regimen can achieve a very good partial response or better, potentially controlling the disease without requiring continuous therapy. Participants will take the drugs for a set period, then stop, with close monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center (Data Collection Only)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
-
Memoral Sloan Kettering Monmouth
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib, venetoclax, and rituximab
What this could lead to
If successful, this could offer a time-limited, chemotherapy-free treatment option that controls Waldenström's macroglobulinemia without needing lifelong therapy.
What could go wrong
This is a small, early-phase (Phase 2) study with only 40 participants. The combination may cause side effects like infections or blood cell issues, and it is not yet known if it works better than standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.